• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[原发性乳腺癌中雌激素受体、孕激素受体与葡萄糖-6-磷酸脱氢酶活性之间关系的研究]

[A study on the relationship among estrogen receptor, progesterone receptor and glucose-6-phosphate dehydrogenase activity in primary breast cancer].

作者信息

Zeng Q F, Xu J H

机构信息

Department of Pathology, Hunan Medical University, Changsha.

出版信息

Zhonghua Bing Li Xue Za Zhi. 1991 Jun;20(2):107-9.

PMID:1914015
Abstract

The relationships among estrogen receptor (ER), progesterone receptor (PgR) and glucose-6-phosphate dehydrogenase (G6PD) activity demonstrated by histochemical technique were studied in 85 cases of primary breast cancer. The ER positive rate was 71.8% and the PgR positive rate was 54.1%. A close correlation was obtained between the PgR and ER positivity or the semiquantitative grades. The G6PD activity in ER or PgR positive group was higher than that in the negative group. Moreover, the elevated G6PD activity was also correlated with the increased semiquantitative grades of ER or PgR. Our findings support the views that both PgR and G6PD are proteins induced by estrogen and may represent markers of functional ER in breast cancer. This suggests that simultaneous assay of ER, PgR and/or G6PD activity may be more reliable to predict the hormone dependence of the tumor.

摘要

采用组织化学技术研究了85例原发性乳腺癌中雌激素受体(ER)、孕激素受体(PgR)与葡萄糖-6-磷酸脱氢酶(G6PD)活性之间的关系。ER阳性率为71.8%,PgR阳性率为54.1%。PgR与ER阳性或半定量分级之间存在密切相关性。ER或PgR阳性组的G6PD活性高于阴性组。此外,G6PD活性升高也与ER或PgR半定量分级增加相关。我们的研究结果支持以下观点:PgR和G6PD都是雌激素诱导的蛋白质,可能代表乳腺癌中功能性ER的标志物。这表明同时检测ER、PgR和/或G6PD活性可能更可靠地预测肿瘤的激素依赖性。

相似文献

1
[A study on the relationship among estrogen receptor, progesterone receptor and glucose-6-phosphate dehydrogenase activity in primary breast cancer].[原发性乳腺癌中雌激素受体、孕激素受体与葡萄糖-6-磷酸脱氢酶活性之间关系的研究]
Zhonghua Bing Li Xue Za Zhi. 1991 Jun;20(2):107-9.
2
Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.乳腺癌中雌激素和孕激素受体的免疫组织化学测定:与科特迪瓦302例患者临床病理因素的关系
BMC Cancer. 2017 Feb 7;17(1):115. doi: 10.1186/s12885-017-3105-z.
3
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.雌激素受体(ER)和孕激素受体(PgR),通过配体结合分析与ER、PgR和pS2相比较,采用免疫组织化学法预测转移性乳腺癌对他莫昔芬的反应:一项西南肿瘤学组研究。
Int J Cancer. 2000 Mar 20;89(2):111-7.
4
Estrogen & progesterone receptors measurement in breast cancer with enzyme-immunoassay & correlation with other prognostic factors.采用酶免疫分析法测定乳腺癌中的雌激素和孕激素受体及其与其他预后因素的相关性
Indian J Med Res. 1992 Feb;96:1-8.
5
Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors.人乳腺癌中核受体的免疫定量分析:与胞质雌激素和孕激素受体的关系
Cancer Res. 1987 Apr 1;47(7):1830-5.
6
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.高危早期乳腺癌中雌激素受体、孕激素受体和微管相关蛋白Tau的基因表达:在希腊合作肿瘤学组试验背景下寻找治疗获益的分子预测指标
Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.
7
Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?雌激素受体阴性孕激素受体阳性乳腺癌——“无人之地”还是只是一种假象?
Cancer Treat Rev. 2018 Jun;67:78-87. doi: 10.1016/j.ctrv.2018.05.005. Epub 2018 May 16.
8
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.重新评估辅助性乳腺癌试验:通过免疫组化法与提取法评估激素受体状态。
J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81. doi: 10.1093/jnci/djj415.
9
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.高Ki-67表达和低孕激素受体表达可独立导致雌激素受体阳性且人表皮生长因子受体2阴性的绝经后乳腺癌患者预后较差。
Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.
10
Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay.雌激素和孕激素受体的定量荧光细胞测量:与激素结合测定的相关性
Breast Cancer Res Treat. 2003 Jul;80(1):1-13. doi: 10.1023/A:1024462416640.